tracken
Sangamo Therapeutics, Inc. Aktie News
Neutral
Business Wire
●
10 Tage alt
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease.
Neutral
Seeking Alpha
●
etwa 2 Monate alt
Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q1 2025 Earnings Conference Call May 12, 2025 6:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Nathalie Dubois-Stringfellow - Chief Development Officer Prathyusha Duraibabu - Chief Financial Officer Conference Call Participants Nicole Germino - Truist L...
Neutral
Business Wire
●
etwa 2 Monate alt
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results.
Neutral
Business Wire
●
etwa 2 Monate alt
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering.
Neutral
Business Wire
●
etwa 2 Monate alt
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS POSTPONES FIRST QUARTER 2025 CONFERENCE CALL TO LATER THE SAME DAY.
Neutral
Business Wire
●
etwa 2 Monate alt
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES FIRST QUARTER 2025 EARNINGS CALL.
Neutral
Business Wire
●
etwa 2 Monate alt
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease.
Neutral
Business Wire
●
2 Monate alt
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS TO PRESENT NEUROLOGY PIPELINE ADVANCES AT THE 28TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT).
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
